volume 26, issue 4, P879-891 2012
DOI: 10.1016/j.idc.2012.08.007
View full text
|
|
Share
Erin T. Jenkins, Donald M. Jensen

Abstract: An increased understanding of viral kinetics has allowed clinicians to tailor therapy for hepatitis C virus through identifying patients who have the best chance of viral eradication and those for whom therapy will likely fail. Nonetheless, sustained viral response rates with pegylated interferon (PegIFN) and ribavirin remain disappointingly low. However, exciting advancements in the field of hepatitis C therapy include the development of new direct-acting antiviral agents, which offer much higher rates of sus…

expand abstract